Navigation Links
OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Date:5/30/2009

ith OGX-011 plus docetaxel. Secondary endpoints included determining objective response and duration of response in those patients with measurable disease at baseline, determining the tolerability and toxicity of weekly OGX-011 and docetaxel when administered in combination, measuring the effect of OGX-011 plus docetaxel or docetaxel alone on serum clusterin levels and describing time to progression and overall patient survival. Baseline characteristics were well balanced between the treatment arms. In addition to the survival results presented and based on a median follow-up of 32 months, data were presented as summarized below.

    -   The OGX-011 plus docetaxel arm met the primary endpoint of the trial
        given that 58% of patients treated with OGX-011 plus docetaxel
        achieved confirmed PSA declines of 50% or greater.

    -   The median number of treatment cycles administered was 9 cycles in
        the OGX-011 plus docetaxel arm compared to 7 cycles in the docetaxel
        arm. The majority of patients either completed all 10 cycles of trial
        treatment (34 patients) or discontinued trial treatment based on
        disease progression (23 patients) or adverse events (14 patients).

    -   Fewer than half as many patients in the OGX-011 plus docetaxel arm
        (7 patients) discontinued trial treatment early for PSA progression
        and/or objective disease progression compared to the docetaxel arm
        (16 patients). Of the 9 patients in the OGX-011 arm that discontinued
        for adverse events, 7 of these patients experienced adverse events
        during the 8th and 9th treatment cycles.

    -   Evidence of a pharmacodynamic effect in the OGX-011 plus docetaxel
        arm was observed with statistically significant declines in serum
        clusterin levels within the first cycle of trial treatment when
        compared to levels in the docetaxel arm. OGX-011 has been shown to
        
'/>"/>
SOURCE  OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
2. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
3. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
4. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
5. OncoGenex Reports First Quarter Financial Results
6. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
7. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
8. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
9. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
10. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
11. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013 Senomyx , ... proprietary taste science technologies to discover, develop, and commercialize ... Linemeyer , Ph.D., the Company,s Vice President, Biology ... Investor Relations & Corporate Communications, will present an overview ... at 10:25 a.m. Eastern Time (7:25 a.m. Pacific Time) ...
(Date:5/24/2013)... 2013 Vestiage, Inc. (stock symbol ... on science-based research and development, sales and marketing ... nutraceuticals, announced today that it is awarding exclusive ... sale of Reluma Skin Illuminating Facial Care. Qualified ... by sending an email to info(at)vestiageinc(dot)com and putting ...
(Date:5/23/2013)... , May 23, 2013 Venaxis, Inc. (Nasdaq: ... focused on obtaining FDA clearance and commercializing its rapid, ... the pricing of an underwritten public offering of 10,000,000 ... purchase 3,500,000 shares of its common stock at an ... public offering price of $1.25 per share and related ...
(Date:5/23/2013)... Patheon Inc ., a leading provider of contract ... will host a complimentary webinar on “Cleaning Validation: Science, ... 4, 2013 at 11 a.m. Eastern Standard Time. ... regulations for cleaning validation. Many companies have incorporated ... evaluation of risk. Some companies have chosen to ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... Mass., Sept. 4 Hologic, Inc.,(Nasdaq: HOLX ) ... presenting at the Morgan Stanley Global Healthcare Unplugged,Conference being ... in New,York, NY., Interested parties are invited to ... on Tuesday, September 9, 2008, at 1:35 PM.,Eastern Time ...
... InVitria,( http://www.invitria.com ), a leading ... enhance productivity, safety and time to ... culture, life science research and,diagnostics industry, ... 4th Annual "Optimizing Cell Culture Development" ...
... Second Round of Funding Supports Commercialization of Recently FDA-cleared ... Pathwork(R) Tissue of ... a,molecular diagnostics company focused on oncology, announced the closing,today of ... the heels of FDA,s clearance for the Pathwork(R) Tissue of ...
Cached Biology Technology:Hologic to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2InVitria Sponsors Cambridge Healthtech's Optimizing Cell Culture Development Conference 2Pathwork Diagnostics Closes $20M Financing 2
(Date:5/23/2013)... and fastest growing open-access publishers, announces the launch ... and Biotechnology . , A broad scope ... and Biotechnology will provide a single open-access ... research to be disseminated and discussed. , ... provide an open-science and interactive web platform for ...
(Date:5/22/2013)... (NLST) investigators also conclude that the 20 percent ... tomography (LDCT) versus chest X-ray (CXR) screening previously ... at experienced screening centers in the United States. ... with their patients about the benefits and risks ... in the New England Journal of Medicine ...
(Date:5/22/2013)... 2013)The omega 3 fatty acids in fish oil have ... so that the American Heart Association currently recommends eating ... fatty varieties rich in omega 3s. However, the mechanism ... a new study, scientists led by Jason R. Carter ... by providing evidence that fish oil might specifically counteract ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in Bioengineering and Biotechnology 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3Fish oil may help the heart beat mental stress 2
... are eating their way through our national forests, destroying ... If enforcement efforts to prevent their importation aren,t stepped ... can expect to fork over billions of dollars by ... BioScience . Researchers at the University of ...
... found aboard the RMS Titanic, which is contributing to ... threat to the exterior of ships and underwater metal ... report their findings in the latest issue of the ... published on 8 December, isolated the micro-organisms from a ...
... a feature unique to humans and pets. Scientists at ... brown trout have individual characters and show different personalities. ... at the University of Gothenburg has for many years ... the west coast of Sweden. "My results show ...
Cached Biology News:Ravenous foreign pests threaten national treasures 2New microscopic life aboard the RMS Titanic 2
... Designed to meet the needs ... animal component-free medium supports fast ... cell densities, while maintaining high ... protein production using the Baculovirus ...
... series of media originally developed at the USDA ... the large scale propagation of cells from the ... for the growth and maintenance of cell lines ... in these cell lines. One of the most ...
... The LIC Duet™ GST•Tag™ Ek Adaptor encodes ... ribosome binding site (rbs), ATG translation initation ... The GST•Tag sequence has been reported to ... the solubility of its fusion partners. The ...
... The LIC Duet™ T7•Tag ® Ek ... operator, ribosome binding site (rbs), ATG ... coding sequence. The T7•Tag is a small ... for detection of the target protein with ...
Biology Products: